BMI_Logo-_NEW_2022.jpg

slogan2

301-378-2551
124 Byte Drive, Frederick, MD 21702

Contact Us Form

"Bringing Creativity to the Biomedical Industry"

ultraINACTIVATIONWith this patented technology pathogens are complexed with a manganese-decapeptide-phosphate (MDP) and then exposed to UV light. Advantages include a quick, easy, and reproducible process all while lowering manufacturing process costs. The MDP system has been adapted from radiation-resistant bacteria such as Deinococcus radiodurans. The front runner of this technology is ultraIPV. More information about ultraIPV can be found at https://bmi-vaccine.net  

UltraIPVultraIPVTM vaccine project working towards IND enabling studies. Mission is to engineer potential commercial UVC inactivation device, produce GLP/GMP-like lots for animal safety and efficacy studies, and prepare regulatory documentation for IND application. (funded by Phase IIb NIAID Research Grant)

 

ultraBAUMVaccine project working towards the finalization of a lead candidate for an Acinetobacter Baumannii species. The UVC inactivation platform was utilized on selected planktonic and biofilm cultures with MDP and tested at WRAIR in mice. [Preliminary data was funded by Phase II NIAID Research Grant]

 

lt blue sq1For further information, please use our Contact Us Form

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok